Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis

Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis

Numerous clinical studies published in the Chinese language support the use of Medilac-S (<i>Bacillus subtilis</i> R0179 and <i>Enterococcus faecium</i> R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel...

Full description

Bibliographic Details
Main Authors: Annie Tremblay, Xiaoyu Xu, James Colee, Thomas A. Tompkins, Sylvie Binda
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Gastroenterology Insights
Subjects:
probiotics
irritable bowel syndrome
Medilac-S
meta-analysis
systematic review
Online Access:https://www.mdpi.com/2036-7422/14/4/36

Similar Items

Similar Items